Headlines about Fresenius Medical Care Corporation (NYSE:FMS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fresenius Medical Care Corporation earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0631525893961 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Artificial vital organs & medical bionics market spurred by increasing demand for organs implantation (whatech.com)
- Critical Care System Market – Advanced Technologies & Growth Opportunities in Industry By 2022 (medgadget.com)
- New study: Intravenous access devices market forecast 2017-2022 (whatech.com)
- Ambulatory Care Services Market by Technology, Growth, Application & Geography – Analysis & Forecast to 2022 (medgadget.com)
- Saudi Arabia Medical Devices Market is Projected to Grow at a CAGR of ~9.5% by 2023 (emailwire.com)
FMS has been the subject of a number of research analyst reports. Royal Bank Of Canada reaffirmed a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care Corporation in a research report on Wednesday, September 13th. Zacks Investment Research raised Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research report on Tuesday, July 11th. DZ Bank AG reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Monday, August 7th. BidaskClub lowered Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $48.33.
Fresenius Medical Care Corporation (NYSE FMS) opened at 47.99 on Friday. The company has a market capitalization of $29.45 billion, a price-to-earnings ratio of 20.60 and a beta of 0.48. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The stock has a 50 day moving average price of $48.19 and a 200 day moving average price of $46.76.
Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by ($0.05). Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the business earned $0.96 earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. On average, equities analysts expect that Fresenius Medical Care Corporation will post $2.35 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Fresenius Medical Care Corporation (FMS) Earns Daily News Sentiment Rating of 0.20” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://sportsperspectives.com/2017/10/13/fresenius-medical-care-corporation-fms-earns-daily-news-sentiment-rating-of-0-20.html.
About Fresenius Medical Care Corporation
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.